22q11.2DS(DGS) deletion syndrome is a rare and phenotypically variable multiorgan syndrome, currently without any cure. Our aim is to develop a standardized approach to formulate pharmacological products useful for clinical trials direct to prevent some serious clinical manifestations of adolescence and adulthood, such as neuropsychiatric and musculoskeletal diseases, or to eliminate or improve cardiovascular defects during embryonic development.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 3 of 3
Large-scale synthesis of inorganic colloidal TiO2@WO3-x nanoheterostructures based on multicomponent semiconductor (TiO2)-plasmonic (WO3-x) heterojunctions.
The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.